​Pulmatrix shares climb as generic Spiriva hits goals in early-stage trial

An inhalable drug for chronic obstructive pulmonary disease, or COPD, being developed by Lexington biotech Pulmatrix and drug giant Mylan, met its goals in an early-stage trial, potentially clearing the way to be marketed in Europe. The news boosted the stock price of the small local biotech by 10 percent this morning to $2.45 a share, giving the company a market value of $36 million. Pulmatrix (Nasdaq: PULM) has a method of delivering drugs using a dry powder it calls iSPERSE which it says is…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

In this study, Nanocomposite Microparticles (NCMPs) of microRNA (miR-146a) containing PGA-co-PDL nanoparticles (NPs) for dry powder inhalation were formulated using L-leucine and mannitol. The spray-drying (Buchi B290) process was optimised and used to incorporate NPs into NCMPs using mix of L-leucine and mannitol excipients in different ratios (F1; 100:0 % w/w, F2; 75:25 % w/w, F3; 50:50 % w/w, F4; 25:75 % w/w, F5; 0:100 % w/w) to investigate yield %, moisture content, aerosolisation performance and miR-146a biological activity. The optimum condition was performed at feed rate 0.5 mL/min, aspirator rate 28 m3/h, atomizing...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conclusions: COPD was more frequently diagnosed among adults with WRA than those with non-WRA, and adults diagnosed with both WRA and COPD appear to have more severe adverse asthma outcomes than those with non-WRA and no COPD. PMID: 31303076 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
(Natural News) Antidepressants and antihistamines are among the most common types of medications people take, and they belong to a class of drugs known as anticholinergics. These drugs can treat a variety of health problems, including COPD, asthma, depression, dizziness, gastrointestinal problems, overactive bladder, and the symptoms of Parkinson’s. Although they can be effective, a...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Condition:   COPD Intervention:   Behavioral: Education about particulate matter practice score Sponsors:   Sei Won Lee;   Korea Centers for Disease Control & Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Point-of-care testing could help reduce antibiotic use in patients with exacerbations of COPD,  study results published in the New England Journal of Medicine show.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
ConclusionsInvestigators should consider including these preferences when designing ePRO assessments. Incorporating patient preferences for ePRO design can ultimately help reduce patient burden and increase engagement, compliance, and improve data quality.
Source: The Patient - Patient-Centered Outcomes Research - Category: International Medicine & Public Health Source Type: research
Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators) and corticosteroids, and more recently, monoclonal antibody therapies (biologics) targeting specific cytokines and their functions. Although these approaches provide relief from exacerbations, questions remain on their long-term efficacy and safety. Furthermore, current therapeutics do not address progressive airway remodeling (AR), a key pathological feature of severe obstructive lung disease. Strikingly, agonists of the bitter taste receptors (TAS2Rs) deli...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
AbstractCigarettes are well-recognized risk factors responsible for the emergence of a variety of pathologic conditions affecting both the airways and the lungs. Smoking-related lung diseases can be classified as chronic obstructive pulmonary disease (COPD) and several types of interstitial diseases, such as pulmonary Langerhans cell histiocytosis, bronchiolitis, desquamative interstitial pneumonitis, acute eosinophilic pneumonia, and interstitial fibrosing lung diseases. The evidence of combined lower lung fibrosis and predominant upper lung emphysema is renowned as a distinct clinical entity, named combined pulmonary fib...
Source: Insights into Imaging - Category: Radiology Source Type: research
Conclusion In spite of health care professionals  feeling comfortable with their counseling practices, the majority of patients reported dissatisfaction with the information they provided about medicine, and three out of four patients were making critical mistakes in the use of inhalers. More effort is warranted by health care professionals on pa tient education to limit critical mistakes.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
Conditions:   COPD;   Obstructive Pulmonary Disease Intervention:   Other: Yoga breathing exercises and Meditation Sponsors:   Chest Research Foundation, India;   Jupiter Hospital, India Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Chronic Obstructive Pulmonary | Health | Health Management | Pharmaceuticals | Spiriva | Tiotropium